echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: Nivolumab adjuvant treatment program was successfully used in the Phase III clinical study of patients with advanced esophagus or gastroesophageal junction cancer

    NEJM: Nivolumab adjuvant treatment program was successfully used in the Phase III clinical study of patients with advanced esophagus or gastroesophageal junction cancer

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Esophageal cancer is the seventh most common tumor in the world, with more than 500,000 deaths every year.


    Checkmate577, a global, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate the feasibility of the immune checkpoint inhibitor Nivolumab as a postoperative adjuvant treatment for patients with esophageal or gastroesophageal junction cancer.


    immunity

    The study was followed up for an average of 24.


    The median disease-free survival of 532 patients in the Nivolumab treatment group was 22.


    Differences in disease-free survival between groups

    According to the study, for patients with esophageal cancer or gastroesophageal junction cancer who need neoadjuvant radiotherapy and chemotherapy, the adjuvant nivolumab treatment program is significantly better than placebo in terms of disease-free survival .


    For patients with esophageal cancer or gastroesophageal junction cancer who need neoadjuvant chemoradiation, nivolumab adjuvant therapy is significantly better than placebo in terms of disease-free survival.


    Original source:

    Ronan J.


    Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.